BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11264179)

  • 21. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
    Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
    Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
    Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
    J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia.
    Xu B; Song X; Yip NC; Xiao P; Zhang Y; Wang W; Zhou S
    Hematology; 2010 Apr; 15(2):74-80. PubMed ID: 20423567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia.
    Lee RV; Braylan RC; Rimsza LM
    Am J Clin Pathol; 2005 Jan; 123(1):119-24. PubMed ID: 15762287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia.
    Steinbach D; Schramm A; Eggert A; Onda M; Dawczynski K; Rump A; Pastan I; Wittig S; Pfaffendorf N; Voigt A; Zintl F; Gruhn B
    Clin Cancer Res; 2006 Apr; 12(8):2434-41. PubMed ID: 16638849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Neale GA; Coustan-Smith E; Stow P; Pan Q; Chen X; Pui CH; Campana D
    Leukemia; 2004 May; 18(5):934-8. PubMed ID: 15029212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.
    Coustan-Smith E; Sancho J; Hancock ML; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Pui CH; Campana D
    Blood; 2002 Oct; 100(7):2399-402. PubMed ID: 12239148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
    Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
    Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
    Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study.
    Chowdhury S; Bandyopadhyay S; Mandal C; Chandra S; Mandal C
    BMC Cancer; 2008 Feb; 8():40. PubMed ID: 18241334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia.
    Hidaka H; Yagasaki H; Takahashi Y; Hama A; Nishio N; Tanaka M; Yoshida N; Villalobos IB; Wang Y; Xu Y; Horibe K; Chen S; Kadomatsu K; Kojima S
    Leuk Res; 2007 Aug; 31(8):1045-51. PubMed ID: 17267033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
    Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
    Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
    Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
    Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
    Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
    Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
    Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
    DiGiuseppe JA; Fuller SG; Borowitz MJ
    Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.
    Gaipa G; Basso G; Maglia O; Leoni V; Faini A; Cazzaniga G; Bugarin C; Veltroni M; Michelotto B; Ratei R; Coliva T; Valsecchi MG; Biondi A; Dworzak MN;
    Leukemia; 2005 Jan; 19(1):49-56. PubMed ID: 15538405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of MDR1, LRP, BCRP and Bcl-2 genes at diagnosis of childhood all: comparison with MRD status after induction therapy.
    Fedasenka UU; Shman TV; Savitski VP; Belevcev MV
    Exp Oncol; 2008 Sep; 30(3):248-52. PubMed ID: 18806751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia.
    Bühring HJ; Sures I; Jallal B; Weiss FU; Busch FW; Ludwig WD; Handgretinger R; Waller HD; Ullrich A
    Blood; 1995 Sep; 86(5):1916-23. PubMed ID: 7544646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.